<DOC>
	<DOC>NCT02345980</DOC>
	<brief_summary>Despite its beneficial effect, ureteral stents may produce lower urinary tract symptoms (such as dysuria, frequency, urgency, urge incontinence and suprapubic pain) that affect the quality of life and sexual health in 70-80%. This study will be conducted to evalute the role of Phosphodiestrase 5 inhibitor (Sildenafil) in relieving these symptoms.</brief_summary>
	<brief_title>Is There a Role of Phosphodiesterase 5 Inhibitor (Sildenafil) in Relieving Ureteral Stent Related Symptoms, RCT</brief_title>
	<detailed_description>Patient: Patient who will undergo ureteral stent fixation after endoscopic procedures Inclusion criteria: 1. Patient aged from 20-50 years. 2. Sexually active. .Exclusion criteria: 1. Patients who had LUTS before stent fixation. 2. Ureteral stent fixation after open surgery.</detailed_description>
	<mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>1. Patient aged from 2050 years 2. Sexually active 1. Patients who had LUTS before DJ stent fixation 2. DJ stent fixation after open surgery</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>